Figure 3

Expressional changes of essential pyrimidine biosynthetic enzymes regulated by oncogene driven signaling. (A) RNAseq analysis of pyrimidine metabolic pathway (6 h/12 h/24 h). AKG: α-ketoglutarate, GLU: glutamate, GLN: glutamine, CarP: carbamoyl phosphate, OAA: oxaloacetate, ASP: aspartate, C-ASP: carbamoyl-aspartate, DHO: dihydroorotate, ORO: orotate, TD: thymidine, T: thymine, GLUD: glutamate dehydrogenase, GLUL: glutamate-ammonia ligase, GOT: glutamic-oxaloacetic transaminase, CAD: carbamoyl-phosphate synthetase, aspartate transcarbamylase, and dihydroorotase complex, DHODH: dihydroorotate dehydrogenase, UMPS: UMP synthetase, RRM1/2: ribonucleotide reductase catalytic subunit M1/2, RRM2B: ribonucleotide reductase regulatory TP53, NME: nucleoside diphosphate kinase, DUT: dUTPase, TYMS: thymidylate synthase, DTYMK: deoxythymidylate kinase, TK1: cytosolic thymidine kinase, TYMP: thymidine phosphorylase, SAMHD: SAM and HD domain containing dNTP triphosphohydrolase, T001: enzyme translated from CT. (B) Western blot analysis of MDA-MB-231 cells was carried out to investigate the expression changes of essential pyrimidine biosynthetic enzymes and the oncogene-driven signaling proteins. Original blots are presented in Supplementary Information (Figure Raw data).